232 related articles for article (PubMed ID: 20631605)
1. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma.
Sholl LM; Barletta JA; Yeap BY; Chirieac LR; Hornick JL
Am J Surg Pathol; 2010 Aug; 34(8):1193-8. PubMed ID: 20631605
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer.
Yang F; Gao Y; Geng J; Qu D; Han Q; Qi J; Chen G
Int J Clin Exp Pathol; 2013; 6(12):2846-54. PubMed ID: 24294370
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Kurabe N; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2017 Jan; 8(5):8738-8751. PubMed ID: 28060732
[TBL] [Abstract][Full Text] [Related]
4. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
[TBL] [Abstract][Full Text] [Related]
5. Elevated nuclear CCND1 expression confers an unfavorable prognosis for early stage lung adenocarcinoma patients.
Xu P; Zhao M; Liu Z; Liu Y; Chen Y; Luo R; Fang W
Int J Clin Exp Pathol; 2015; 8(12):15887-94. PubMed ID: 26884860
[TBL] [Abstract][Full Text] [Related]
6. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.
Anagnostou VK; Lowery FJ; Zolota V; Tzelepi V; Gopinath A; Liceaga C; Panagopoulos N; Frangia K; Tanoue L; Boffa D; Gettinger S; Detterbeck F; Homer RJ; Dougenis D; Rimm DL; Syrigos KN
BMC Cancer; 2010 May; 10():186. PubMed ID: 20459695
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients.
Wu Y; Huang B; Liu Q; Liu Y
Int J Clin Exp Pathol; 2015; 8(7):8252-9. PubMed ID: 26339394
[TBL] [Abstract][Full Text] [Related]
8. Chaperone protein L-isoaspartate (D-aspartyl) O-methyltransferase as a novel predictor of poor prognosis in lung adenocarcinoma.
Saito H; Yamashita M; Ogasawara M; Yamada N; Niisato M; Tomoyasu M; Deguchi H; Tanita T; Ishida K; Sugai T; Yamauchi K
Hum Pathol; 2016 Apr; 50():1-10. PubMed ID: 26997432
[TBL] [Abstract][Full Text] [Related]
9. Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas.
Zhan P; Shen XK; Qian Q; Wang Q; Zhu JP; Zhang Y; Xie HY; Xu CH; Hao KK; Hu W; Xia N; Lu GJ; Yu LK
Oncol Rep; 2012 Apr; 27(4):1072-8. PubMed ID: 22200856
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
[TBL] [Abstract][Full Text] [Related]
11. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer.
Wilbertz T; Wagner P; Petersen K; Stiedl AC; Scheble VJ; Maier S; Reischl M; Mikut R; Altorki NK; Moch H; Fend F; Staebler A; Bass AJ; Meyerson M; Rubin MA; Soltermann A; Lengerke C; Perner S
Mod Pathol; 2011 Jul; 24(7):944-53. PubMed ID: 21460799
[TBL] [Abstract][Full Text] [Related]
12. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.
Xu XY; Lin N; Li YM; Zhi C; Shen H
Pathol Res Pract; 2013 Jun; 209(6):345-52. PubMed ID: 23602236
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
14. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
15. Loss of CD44 and SOX2 expression is correlated with a poor prognosis in esophageal adenocarcinoma patients.
Honing J; Pavlov KV; Meijer C; Smit JK; Boersma-van Ek W; Karrenbeld A; Burgerhof JG; Kruyt FA; Plukker JT
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S657-64. PubMed ID: 24833101
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.
Suzuki K; Kadota K; Sima CS; Nitadori J; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
J Clin Oncol; 2013 Feb; 31(4):490-8. PubMed ID: 23269987
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer.
Ruan J; Wei B; Xu Z; Yang S; Zhou Y; Yu M; Liang J; Jin K; Huang X; Lu P; Cheng H
Med Oncol; 2013 Mar; 30(1):445. PubMed ID: 23307254
[TBL] [Abstract][Full Text] [Related]
18. Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival.
Singhi AD; Foxwell TJ; Nason K; Cressman KL; McGrath KM; Sun W; Bahary N; Zeh HJ; Levy RM; Luketich JD; Davison JM
Am J Surg Pathol; 2015 Apr; 39(4):487-95. PubMed ID: 25634752
[TBL] [Abstract][Full Text] [Related]
19. IMP3 can predict aggressive behaviour of lung adenocarcinoma.
Beljan Perak R; Durdov MG; Capkun V; Ivcevic V; Pavlovic A; Soljic V; Peric M
Diagn Pathol; 2012 Nov; 7():165. PubMed ID: 23190601
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.
Schilsky JB; Ni A; Ahn L; Datta S; Travis WD; Kris MG; Chaft JE; Rekhtman N; Hellmann MD
Lung Cancer; 2017 Jun; 108():205-211. PubMed ID: 28625636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
